Skip to main content
single10MG

Ipamorelin

10MG Protocol

Ipamorelin 10MG

Injection Freq.

Inject once daily

Cycle Sched.

8–12 weeks; optional extension to 16 weeks, followed by 2–4 week off-cycle

Reconstitution

3.0 mL BAC water

Supports lean-mass and recovery signaling via GH-mediated anabolic processes
Supports fat-metabolism and favorable body-composition changes over time
High selectivity for GH release with minimal ACTH/cortisol/prolactin impact
May support gastric motility and digestive function
1

Reconstitution Requirements

  • 3.0 mL BAC water
StepWeek RangeDoseUnits
1Weeks 1–2100 mcg3
2Weeks 3–4150 mcg5
3Weeks 5–8200 mcg6
4Weeks 9–12250 mcg8

Inject once daily

8–12 weeks; optional extension to 16 weeks, followed by 2–4 week off-cycle

Ipamorelin is presented as a highly selective growth-hormone secretagogue that binds the growth hormone secretagogue receptor (GHSR-1a). By activating this receptor, it prompts the pituitary to release endogenous growth hormone in a short, pulsatile pattern rather than producing continuous exposure. The protocol notes that after subcutaneous administration, growth hormone typically peaks in roughly 40 minutes and returns to baseline within about 2–3 hours, a kinetic profile that aligns with once-daily research use when the goal is to mimic physiologic GH rhythms. A key differentiator described on the page is selectivity: unlike some older secretagogues, ipamorelin does not meaningfully stimulate ACTH, cortisol, or prolactin at effective doses. The page also highlights a secondary mechanism—GHSR-1a activity in the gastrointestinal tract—where ipamorelin has demonstrated pro-motility effects, including accelerated gastric emptying in preclinical/clinical observations.
Mild injection-site reactions (redness/swelling)
Very rare water retention
Very rare increased hunger
  • Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
  • Add diluent slowly down the vial wall to minimize foaming
  • Gently swirl/roll until fully dissolved (do not shake)
  • Label vial with reconstitution date and concentration; protect from light
  • Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
  • Avoid repeated freeze–thaw cycles
  • Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
  • Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)